X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Featured

Bioavailability Enhancement Market Projects CAGR of 11%

Content Team by Content Team
28th February 2023
in Featured, Market Moves, News

Since more biopharmaceutics classification system- BCS II as well as BCS IV molecules are being evaluated in the early stages of development, one of the market reports has signalled that the bioavailability enhancement market is expected to grow at a stable rate between 2022 and 2035.

A CAGR of 11% is anticipated for the market in the forecast bracket, as per the report.

 

Given that more than 40% of the marketed medicines are perceived to be having low bioavailability, the report pointed out that in recent years there has been a rise in the number of drug developers analysing numerous re-formulation tactics so as to enhance the bioavailability of the current drug candidates. The research predicts that within the forecast period, the demand for bioavailability enhancement drug formulations is anticipated to grow quite significantly.

 

Given the sector’s shifting aim towards lipophilic drug compounds, the existing market players are looking to identify bioavailability enhancement techniques so as to mitigate the challenge when it comes to low bioavailability and stability, as per the research.

 

Developers of drugs have gone on to demonstrate preference when it comes to being reliant on bioavailability enhancement service as well as tech providers in order to leverage cost and also research timelines.

According to the research, outsourcing happens to be a preferred model for upgrading drug bioavailability, and because of this, by late 2022, almost 115 companies were found to be giving out these kinds of services.

When it comes to the technological approach, the report also covered the gamut of solubility enhancement, sustained release, and absorption enhancement.

 

More than half of the technologies were found to focus on elevating small molecules’ bioavailability. They were specifically for small molecules that were intended for oral drug delivery. The report otherwise noted that the distribution when it comes to other types of these technologies was 31% for small molecules as well as biologics and 16% only for biologics.

 

Lipid nanoparticles were a preferred choice of numerous service providers who were wanting to improve the bioavailability of weak soluble drugs. This was because of elements such as drug loading capacity as well as long-term physical stability.

 

Interestingly, enough mergers and acquisitions have been witnessed in this market, as per the report. This is because service providers want to offer multiple services in order to cater to the varied customer needs.

Besides, in order to maintain a competitive edge across the market segment, there are many stakeholders who are engaged in the development of proprietary technology that is based on bioavailability enhancers as well as sustained release principles.

Previous Post

Booming Performance By The Life Sciences Biz In Wales

Next Post

Animal Testing Could See An End With An Artificial Model

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post

Animal Testing Could See An End With An Artificial Model

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In